Ampicillin-sulbactam basecompared Colistin Basefor the treatment of ?acintobacter resistant to carbapenems in ventilator associated pneumonia ?

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N126

Enrollment

Registered

2019-12-17

Start date

2018-06-22

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventilator associated pneumonia ?. Ventilator associated pneumonia

Interventions

Intervention 1: Intervention group: Cholestine plus Carbapenem is prescribed in doses based on renal clearance and milligram in kilogram and converted to millions of units intravenously. We inject 500

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Ages over 16 years Ventilator-induced pneumonia with carbapenem-producing acinetobacter

Exclusion criteria

Exclusion criteria: Failure to complete the course of treatment and discontinuation of treatment (due to drug complications and death, etc.) Dissatisfaction

Design outcomes

Primary

Measure	Time frame
White blood cell count. Timepoint: First study, third day, seventh day and 14th day. Method of measurement: Blood test.;Erythrocyte sedimentation rate. Timepoint: First study, third day, seventh day and 14th day. Method of measurement: Blood test.;Culture of lung secretions. Timepoint: First study, third day, seventh day and 14th day. Method of measurement: Culture of lung secretions test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Masoumeh Sofian

Arak University of Medical Sciences

sofian@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026